Shrestha Bhattarai, Tripti http://orcid.org/0000-0002-7910-2565
Shamu, Tambudzai
Gorelick, Alexander N.
Chang, Matthew T.
Chakravarty, Debyani http://orcid.org/0000-0001-8629-5732
Gavrila, Elena I.
Donoghue, Mark T. A.
Gao, JianJong
Patel, Swati
Gao, Sizhi Paul
Reynolds, Margaret H.
Phillips, Sarah M.
Soumerai, Tara
Abida, Wassim
Hyman, David M. http://orcid.org/0000-0001-8150-9762
Schram, Alison M. http://orcid.org/0000-0002-6070-2413
Solit, David B. http://orcid.org/0000-0002-6614-802X
Smyth, Lillian M.
Taylor, Barry S. http://orcid.org/0000-0002-3355-9471
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA204749, P30 CA008748, U54 OD020355)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 3 October 2019
Accepted: 25 March 2022
First Online: 19 April 2022
Competing interests
: The authors declare the following competing interests: L.M.S. reports receiving research funding from AstraZeneca, Puma Biotechnology and Roche Genentech; honoraria from AstraZeneca and Pfizer; travel, accommodations, expenses from Puma Biotechnology, Roche Genentech and Pfizer; and consulting or advisory board activities for Roche Genentech and AstraZeneca. D.B.S. reports advisory board activities for Loxo Oncology, Pfizer, Illumina, Lilly Oncology, Vivideon, and Intezyne. D.M.H. reports receiving research funding from AstraZeneca, Puma Biotechnology, Loxo Oncology and personal fees from Atara Biotherapeutics, Chugai Pharma, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer, Debiophram Group, and Genentech. B.S.T. reports advisory board activities for Boehringer Ingelheim, Loxo Oncology (a wholly owned subsidiary of Eli Lilly), and honoraria and research funding from Genentech. All stated activities were outside of the work described herein. No other disclosures were noted.